Selumetinib plus dacarbazine versus placebo plus dacarbazine as first-line treatment for BRAF-mutant metastatic melanoma: a phase 2 double-blind randomised study
Year: 2013
Type: article
Study designs: Randomized Controlled Trial, Clinical Trial
Source: The Lancet Oncology
Institutions: Institut Gustave Roussy, University Hospital Zurich, Medizinische Hochschule Hannover, The Christie NHS Foundation Trust, The University of Texas MD Anderson Cancer Center, Oslo University Hospital, Hospital Clínic de Barcelona, Országos Idegsebészeti Tudományos Intézet, Essen University Hospital, AstraZeneca (United Kingdom), Churchill Hospital, Oxford University Hospitals NHS Trust
Language: English
Topic: Melanoma and MAPK Pathways
Subfield: Molecular Biology
Domain: Life Sciences
Open Access status: green
OpenAlex ID: W2164996207
